GlassScriptPhysician profile
Adrianne L Echelbarger
NPI 1588058614
$4,055.37
in general payments reported to CMS, 2019-2025
24 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $1,158 · 2023: $774 · 2024: $834 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $644.12 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $604.78 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $396.49 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.02 | 2022-2024 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $241.32 | 2022-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $214.08 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $201.12 | 2022-2025 | Dupixent |
| Genzyme Corporation | $188.06 | 2022-2025 | |
| Amgen INC. | $180.48 | 2021-2025 | Tezspire |
| Inari Medical, INC. | $177.74 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.79 | 2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $106.37 | 2022-2025 | Acthar |
| Philips North America LLC | $103.43 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $85.33 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $84.19 | 2022-2025 | Prolastin-C Liquid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $83.25 | 2024 | |
| Viatris Specialty LLC | $66.08 | 2025 | Yupelri |
| Abbvie INC. | $51.13 | 2025 | |
| Merck Sharp & Dohme LLC | $45.45 | 2025 | Zerbaxa |
| United Therapeutics Corporation | $32.73 | 2024 | Tyvaso |
| Verona Pharma, INC. | $23.05 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $22.87 | 2021 | |
| Inogen, INC. | $18.00 | 2024 | |
| Chiesi USA, INC. | $15.49 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianne Echelbarger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.